{
  "schema_version": 1,
  "kind": "drug_profile",
  "generic": "silver sulfadiazine",
  "review_status": "reviewed",
  "origin": "openfda",
  "sections": {
    "adult": [
      {
        "text": "Prompt institution of appropriate regimens for care of the burned patient is of prime importance and includes the control of shock and pain. The burn wounds are then cleansed and debrided; silver sulfadiazine cream, USP 1% is then applied under sterile conditions. The burn areas should be covered with silver sulfadiazine cream, USP 1% at all times. The cream should be applied once to twice daily to a thickness of approximately one sixteenth of an inch.",
        "source": "US FDA label for silver (Silver Sulfadiazine), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/silver.json",
        "verbatim": true
      }
    ],
    "child": [
      {
        "text": "Safety and effectiveness in children have not been established. (See CONTRAINDICATIONS )",
        "source": "US FDA label for silver (Silver Sulfadiazine), section 'pediatric use', retrieved 2026-08-29",
        "cached_file": "labels/silver.json",
        "verbatim": true
      }
    ],
    "renal": [
      {
        "text": "No kidney-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for silver (Silver Sulfadiazine), retrieved 2026-08-29",
        "cached_file": "labels/silver.json",
        "verbatim": false
      }
    ],
    "hepatic": [
      {
        "text": "No liver-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for silver (Silver Sulfadiazine), retrieved 2026-08-29",
        "cached_file": "labels/silver.json",
        "verbatim": false
      }
    ],
    "pregnancy": [
      {
        "text": "TERATOGENIC EFFECTS: Pregnancy Category B.",
        "source": "US FDA label for silver (Silver Sulfadiazine), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/silver.json",
        "verbatim": true
      },
      {
        "text": "A reproductive study has been performed in rabbits at doses up to three to ten times the concentration of silver sulfadiazine in silver sulfadiazine cream, USP 1% and has revealed no evidence of harm to the fetus due to silver sulfadiazine.",
        "source": "US FDA label for silver (Silver Sulfadiazine), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/silver.json",
        "verbatim": true
      },
      {
        "text": "There are, however, no adequate and well-controlled studies in pregnant women.",
        "source": "US FDA label for silver (Silver Sulfadiazine), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/silver.json",
        "verbatim": true
      }
    ],
    "lactation": [
      {
        "text": "It is not known whether silver sulfadiazine cream, USP 1% is excreted in human milk.",
        "source": "US FDA label for silver (Silver Sulfadiazine), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/silver.json",
        "verbatim": true
      },
      {
        "text": "However, sulfonamides are known to be excreted in human milk and all sulfonamides derivatives are known to increase the possibility of kernicterus.",
        "source": "US FDA label for silver (Silver Sulfadiazine), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/silver.json",
        "verbatim": true
      },
      {
        "text": "Because of the possibility for serious adverse reactions in nursing infants from sulfonamides, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.",
        "source": "US FDA label for silver (Silver Sulfadiazine), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/silver.json",
        "verbatim": true
      }
    ]
  }
}